ELI LILLY & Co is 595.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($1.093 T vs $1.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | STOK | LLY |
|---|---|---|
| Market cap | $1.84 B | $1.093 T |
| US-listed rank | #2166 | #11 |
| Revenue (latest FY) | $184.42M | $65.18B |
| Net income (latest FY) | -$6.88M | $20.64B |
| Net margin | -3.7% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 588 | 989 |
ELI LILLY & Co is 595.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($1.093 T vs $1.84 B).
In their latest fiscal years, Stoke Therapeutics, Inc. reported $184.42M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Stoke Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.